Why Ocugen Shares Are Falling

Ocugen Inc OCGN shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.

Ocugen says the company intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN.

Get Started

Trade Bitcoin, Ethereum, and More Instantly — No Wallets, No Hassle

Speculate on price movements, claim up to $200 in bonuses, and start with risk-free paper trading with crypto futures on Plus500.

Get Started

Disclosure: 82% of retail CFD accounts lose money

Ocugen is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.

See Also: Why This Wheat-Focused ETF Is Suddenly On The Radar Of Retail Investors

Ocugen has a 52-week high of $17.65 and a 52-week low of $2.87.